OBJECTIVE: To characterize internists' dosing practices when administering and adjusting intravenous heparin regimens. DESIGN: A survey administered by physician-investigators. SETTING: Two community teaching hospitals and one Veterans Affairs Medical Center. SUBJECTS: Sixty-one attending physicians in internal medicine. MEASUREMENTS: Physicians' choices of therapeutic activated partial thromboplastin time (APTT) range, initial heparin bolus, initial infusion dose, and dose/infusion adjustments when APTT levels are < 1.2 x control (< 35 seconds), 1.2-1.5 x control (35-45 seconds), 1.5-2.3 x control (46-70 seconds), 2.3-3.0 x control (71-90 seconds), and > 3.0 x control (> 90 seconds). RESULTS: Physicians' dosing decisions and therapeutic ranges during heparin treatment varied widely. Responses to nontherapeutic APTT levels had especially high coefficients of variation (0.67-0.81). Two groups of physicians, together comprising a majority of all respondents, use mutually exclusive therapeutic ranges (mean 44-56 seconds and 60-83 seconds). These two groups differ significantly in several types of dosing decisions. CONCLUSION: In the absence of generalizable standard guidelines for intravenous heparin therapy, internists' dosing practices vary widely. Because such practices may impede timely, effective anticoagulation, experimental studies comparing standardized dosing protocols are needed.
OBJECTIVE: To characterize internists' dosing practices when administering and adjusting intravenous heparin regimens. DESIGN: A survey administered by physician-investigators. SETTING: Two community teaching hospitals and one Veterans Affairs Medical Center. SUBJECTS: Sixty-one attending physicians in internal medicine. MEASUREMENTS: Physicians' choices of therapeutic activated partial thromboplastin time (APTT) range, initial heparin bolus, initial infusion dose, and dose/infusion adjustments when APTT levels are < 1.2 x control (< 35 seconds), 1.2-1.5 x control (35-45 seconds), 1.5-2.3 x control (46-70 seconds), 2.3-3.0 x control (71-90 seconds), and > 3.0 x control (> 90 seconds). RESULTS: Physicians' dosing decisions and therapeutic ranges during heparin treatment varied widely. Responses to nontherapeutic APTT levels had especially high coefficients of variation (0.67-0.81). Two groups of physicians, together comprising a majority of all respondents, use mutually exclusive therapeutic ranges (mean 44-56 seconds and 60-83 seconds). These two groups differ significantly in several types of dosing decisions. CONCLUSION: In the absence of generalizable standard guidelines for intravenous heparin therapy, internists' dosing practices vary widely. Because such practices may impede timely, effective anticoagulation, experimental studies comparing standardized dosing protocols are needed.
Authors: P Théroux; H Ouimet; J McCans; J G Latour; P Joly; G Lévy; E Pelletier; M Juneau; J Stasiak; P deGuise Journal: N Engl J Med Date: 1988-10-27 Impact factor: 91.245
Authors: R D Hull; G E Raskob; D Rosenbloom; A A Panju; P Brill-Edwards; J S Ginsberg; J Hirsh; G J Martin; D Green Journal: N Engl J Med Date: 1990-05-03 Impact factor: 91.245
Authors: James W Schurr; Craig A Stevens; Anne Bane; Carol Luppi; Sarah E Culbreth; Amy Leigh Miller; Jean M Connors; Katelyn W Sylvester Journal: Clin Appl Thromb Hemost Date: 2017-08-04 Impact factor: 2.389
Authors: H N Lee; D J Cook; A Sarabia; R Hatala; A McCallum; D King; G H Guyatt; J Dobranowski; P Powers Journal: J Gen Intern Med Date: 1995-06 Impact factor: 5.128